

## Analytical Report

Sample ID	699 - Analysis Service - Q8	sample submitted by <a href="mailto:quasar-chemicals.de">quasar-chemicals.de</a>
Expected	Rilmazafone HCl	
Sample adulterated?	No	
Sample Appearance		
Sample type	Research Chemical -	
Date of sample receipt	11-02-2023	
Date of analysis	11-11-2023	
Date of Report	11-11-2023	

### Qualitative and Quantitative Results

Substances identified	Purity / Quantity	Harm Reduction information	Chemical Class	Pubchem ID	analytical techniques used	
					Identification	Quantification
Rilmazafone	>98 % *	<a href="https://psychonautwiki.org/wiki/Rilmazafone">https://psychonautwiki.org/wiki/Rilmazafone</a>	Benzodiazepine	5069	LCMS	NMR

\* uncertainty of measurement +/- 5 %

***The Analysis Report is not a warranty or advertisement for the quality of any supplier or product!  
We do not claim nor make any guarantees or recommendations regarding the safety of the analysed samples for human consumption.***

*Kykeon Analytics Ltd. assumes no liability for the results or for any damages that may arise from the use of the Analysis Report. The Analysis Report is not to be used for defence purposes in any type of proceeding without the explicit consent of KYKEON, its contents shall not be disclosed to any third party for marketing purposes. The Analysis Report shall not be altered, modified, amended, falsified, forged or changed in any way.*



Detailed information regarding our workflow including a full description of the analytical methods applied

is freely available under <https://www.kykeonanalytics.com/services/users/>

Attachments: LCMS Detailed report  
1H NMR Spectrum  
FTIR Spectrum



# Qualitative Analysis Report



## Sample Information

<b>Name</b>	699_Rilmazafone	<b>Data File Path</b>	D:\Kykeon\Data\2023\11-07\699_RilmazafoneMRM2.d
<b>Sample ID</b>		<b>Acq. Time (Local)</b>	11/7/2023 7:22:59 PM (UTC+01:00)
<b>Instrument</b>	Instrument 1	<b>Method Path (Acq)</b>	D:\Kykeon\methods\dMRM-6minNormalC18_Rilmazafone.m
<b>MS Type</b>	QQQ	<b>Version (Acq SW)</b>	Ultivo LC/TQ C.01.00 (B1677.1 SR1)
<b>Inj. Vol. (ul)</b>	10	<b>IRM Status</b>	
<b>Position</b>	P1-A9	<b>Method Path (DA)</b>	D:\Kykeon\methods\ReportWorkflowMethod-MRM.m
<b>Operator</b>		<b>Result Summary</b>	1 qualified (1 targets)

## Sample Chromatograms



## Compound Summary

Cpd	Name	Formula	Mass	RT	Area	m/z	Algorithm
1	Rilmazafone			3.538	4970	476.0	MRM


# Qualitative Analysis Report

## Compound Details

### Cpd. 1: Rilmazafone


Name	Formula	Mass	RT	Area	m/z	m/z (primary prod.)	CE	FV	Algorithm
Rilmazafone			3.538	4970	476.0	344.0	40.00		MRM

### Compound Chromatograms (overlaid)



### Structure

### MS/MS Spectra





MassHunter Qual 10.0  
(End of Report)




**KYKEON**  
**ANALYTICS**

#699 Rilimazafone HCl  
Purity: >98 %

2023-11-06T18:01:32+0100  
NMReady 100/nanalysis-oc162  
DMSO-d6  
SF: 102.20  
T: 33.3 °C  
NS:32  
d1: 43.0147  
RG: 34.0





Fri Nov 10 23:58:56 2023 (GMT+01:00)

FIND PEAKS:

Spectrum: #699\_Rilmazafone\_HCl

Region: 4000.00 400.00

Absolute threshold: 0.197

Sensitivity: 50

Peak list:

Position:	636.59	Intensity:	0.233
Position:	662.09	Intensity:	0.241
Position:	754.33	Intensity:	0.303
Position:	1093.39	Intensity:	0.260
Position:	1232.15	Intensity:	0.299
Position:	1253.04	Intensity:	0.383
Position:	1266.56	Intensity:	0.287

Position:	1289.17	Intensity:	0.249
Position:	1333.33	Intensity:	0.235
Position:	1396.22	Intensity:	0.260
Position:	1412.21	Intensity:	0.397
Position:	1434.51	Intensity:	0.295
Position:	1488.51	Intensity:	0.426
Position:	1537.69	Intensity:	0.455
Position:	1584.93	Intensity:	0.295
Position:	1630.28	Intensity:	0.698
Position:	1688.25	Intensity:	0.534
Position:	1704.48	Intensity:	0.218
Position:	2660.42	Intensity:	0.265
Position:	2851.32	Intensity:	0.455
Position:	2928.65	Intensity:	0.459
Position:	3021.56	Intensity:	0.389
Position:	3073.09	Intensity:	0.377
Position:	3268.59	Intensity:	0.565